WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc.

October 18, 2007 23:52 ET

WEX Pharmaceuticals Inc.: Appointment of Chief Financial Officer

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 18, 2007) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) is pleased to announce that Mike Lam, B.Sc., MBA, C.A. has been named Chief Financial Officer.

Mr. Lam obtained his B.Sc. in Biochemistry from the University of Alberta in 1976 and his MBA from the University of Western Ontario in 1981. Mr. Lam started his career in chartered accountancy in 1981 with PriceWaterhouseCoopers, first in Winnipeg, then in Hong Kong, and finally in Vancouver. In 1991, Mr. Lam co-founded Lam Lo Nishio, Chartered Accountants, where he remains a partner. His practice areas include tax planning for owner-managed businesses, non-resident investments in Canada, and business advisory services to small and medium- sized enterprises.

"We are very pleased to welcome Mike on board," said Dr. Edge Wang, President & CEO of the Company. "His expertise in Canadian and international business and financial management will be a strong asset as we begin the next phase of the Company's development."

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China.

Forward Looking Statements and Information

This News Release contains forward-looking statements which may not be based on historical fact. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

Contact Information